from february 1983 to january 1985 , 497 patients with advanced breast cancer were randomly allocated to receive either epirubicin or doxorubicin in the following combination chemotherapy regimen : fluorouracil ( 5-fu ) 500 mg/m2 intravenous ( iv ) on days 1 and 8 ;
C0014582
epirubicin
C0013089
doxorubicin